Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 185 Results

Intervention Indication Therapeutic Area Year Actions
Serplulimab with chemotherapy for treating previously untreated extensive stage small-cell lung cancer Serplulimab (HLX10) Small-cell lung cancer (SCLC) Lung and Respiratory Cancer 2023 View  |  Download
Semaglutide for treating overweight or obesity with cardiovascular disease Semaglutide (Ozempic) Cardiovascular disease (CVD) , Obesity Cardiovascular System , Endocrine Nutritional and Metabolic Disorders 2023 View  |  Download
Semaglutide for non-cirrhotic non-alcoholic steatohepatitis Semaglutide (Ozempic) Non-alcoholic steatohepatitis (NASH) Hepatology 2023 View  |  Download
Selumetinib for treating symptomatic, inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in adults Selumetinib (AZD6244; ARRY-142886) Plexiform neurofibromas Neurological Cancer , Neurology 2023 View  |  Download
Selpercatinib for treating advanced solid tumours with RET gene fusion in people aged 12 years and older Selpercatinib (LOXO-292; LY3527723) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Sebetralstat for treating hereditary angioedema Sebetralstat (KVD-900) Hereditary angioedema (HAE) Genetic Disorders , Immunology 2023 View  |  Download
Sarilumab for treating Polyarticular-course Juvenile idiopathic arthritis in children and adolescents Sarilumab Juvenile idiopathic arthritis Rheumatology 2023 View  |  Download
SAR443820 for treating amyotrophic lateral sclerosis (ALS) SAR443820 (DNL788) Amyotrophic lateral sclerosis Neurology 2023 View  |  Download
Sacituzumab govitecan for treating previously untreated locally advanced or metastatic triple negative breast cancer with negative PD-L1 status Sacituzumab Govitecan (IMMU-132; Trodelvy) Breast cancer Breast Cancer 2023 View  |  Download
Sacituzumab govitecan for previously treated advanced non-small cell lung cancer Sacituzumab Govitecan (IMMU-132; Trodelvy) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications